SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (212)1/26/2000 3:47:00 PM
From: Mike McFarland  Read Replies (1) of 438
 
Just got the answer back from Genzyme clarifying
the wording in the GENZ annual--I'd asked whether
Genzyme really owned the assets of the divisions.
The answer I got back was that all of the value of
SAGE, cancer and non-cancer belongs to GZMO and
Genzyme General shareholders have no claims to SAGE.

It was sure nice of them to clarify that for me,
the legal language in the genz annual report was
confusing--Genzyme Corporation is the only legal
entity that can hold assets and liabilities.

So the short answer I think, is that if SAGE turns
out to be the right tool for the job, which in my
mind is for finding these novel transcripts and
antigens (is my terminology okay?) with which to
devise these antigen cocktail vaccines--then GZMO
is the right company in which to invest and not
GENZ.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News